(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 March 2022 (17.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/055893 A1

(51) International Patent Classification:
A61K 31/5025 (2006.01) *A61K 31/53* (2006.01)
A61K 31/517 (2006.01)

(21) International Application Number:
PCT/US2021/049310

(22) International Filing Date:
07 September 2021 (07.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/075,702 08 September 2020 (08.09.2020) US

(71) Applicant: **IDEAYA BIOSCIENCES INC.** [US/US]; 7000 Shoreline Ct, Suite 350, South San Francisco, California 94080 (US).

(72) Inventors: **MOUNIR, Zineb**; 1030 Fassler Avenue, Pacifica, California 94404 (US). **WAGLE, Marie-Claire**; 2648 Martinez Drive, Burlingame, California 94010 (US). **RAVINDRAN, Nandini**; 1121 Hillside Blvd, South San Francisco, California 94080 (US). **PANKAJAKSHAN, Divya**; 1916 Jameston Ln, Daly City, California 94014 (US). **LACKNER, Mark R.**; 746 26th Ave, San Mateo, California 94403 (US).

(74) Agent: **PERDOK, Monique M.** et al.; Schwegman Lundberg & Woessner, P.A., P.O. Box 2938, Minneapolis, Minnesota 55402 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PHARMACEUTICAL COMBINATION AND TUMOR TREATMENT




FIG. 4

(57) Abstract: A combination therapy is described involving a selective protein kinase C inhibitor and a cMET inhibitor, which is useful for treating metastatic uveal melanoma and other proliferative diseases, such as a tumor having a GNAQ or GNA11 mutation. The combination therapy can be provided by a pharmaceutical product, a method of treatment, or a kit. The combination therapy can involve use of a protein kinase C inhibitor and a cMET inhibitor. Also provided are methods useful for selecting patients or directing a course of treatment. In various examples, the protein kinase C can have the structure according to Formula II.

[Continued on next page]

WO 2022/055893 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*